First line Treatment of Traumatic Carotid Cavernous Fistulas Using Covered Stents at Level 1 Regional Trauma Center

Abstract

Objective

The widely accepted treatment option of a traumatic carotid cavernous fistula (TCCF) has been detachable balloon or coils based fistula occlusion. Recently, covered stent implantation has been proving an excellent results. The purpose of this study is to investigate our experiences with first line choice of covered stent implantation for TCCF at level 1 regional trauma center.

Methods

From November 2004 to February 2020, 19 covered stents were used for treatment of 19 TCCF patients. Among them, 15 cases were first line treatment using covered stents. Clinical and angiographic data were retrospectively reviewed.

Results

Procedures were technically successful in all 15 cases (100%). Immediate angiographic results after procedure were total occlusion in 12 patients (80%). All patients except two expired patients had image follow-up (mean 15 months). Recurred symptomatic three patients underwent additional treatments and achieved complete occlusion. Mean clinical follow-up duration was 32 months and results were modified Rankin Scale 1–2 in five, 3–4 in five, and 5 in three patients.

Conclusion

The covered stent could be considered as fist line treatment option for treating TCCF patients especially in unstable vital sign. Larger samples and expanded follow-up are required to further develop their specifications and indications.

INTRODUCTION

Direct carotid cavernous fistula (DCCF) is a direct communication between the internal carotid artery (ICA) and cavernous sinus (CS). DCCF is caused by head and facial trauma or cavernous ICA aneurysm rupture; traumatic CCF (TCCF) accounts for approximately 75% of all direct CCF cases [30]. The arteriovenous shunt between ICA and CS leads to various signs and symptoms including exophthalmos, chemosis, decreased visual acuity, cranial nerve impairment, or life-threatening hemorrhage and epistaxis. However, these characteristics are similar to those of multiple head and facial trauma. Hence, the diagnosis of TCCF may be delayed.

At present, endovascular therapy is the mainstay treatment for TCCF. TCCF is primarily treated with parent artery occlusion, which is a deconstructive method and can be performed in patients with good collateral flow. Reconstructive methods and fistula occlusion with detachable balloons or coils are therapeutic options for failed balloon test occlusion. The use of covered stents, which is another reconstructive treatment option for direct CCF, with encouraging short-to-midterm clinical outcomes, has recently emerged. Hence, the present study aimed to present the diagnosis of TCCF and the use of covered stents as the first-line treatment for TCCF in a level 1 regional trauma center.

MATERIALS AND METHODS

Patient population

The study was approved by the Institutional Review Board of Pusan National University Hospital (IRB No. H-2012-001-097). From November 2004 to February 2020, 19 covered stents were used for the treatment of 19 patients with TCCF. Among these patients, 15 underwent covered stent implantation as the firstline treatment (Graftmaster coronary stent graft system; Abbott Vascular, Rangendingen, Germany). The cohort comprised five women and 10 men with a mean age of 38.7 years (range, 12–63). The mechanisms of injury were motor vehicular accident in three (20%), motorcycle accident in seven (47%), falling in four (27%), and iatrogenic injury after pituitary adenoma surgery in one patient (7%).

The clinical symptoms were categorized as orbital, cavernous, ocular, and cerebral. The orbital symptoms included chemosis, exophthalmos, periorbital pain, and eyelid swelling, which were caused by retrograde venous flow and/or pressure in CS. The cavernous symptoms were ptosis, diplopia, anisocoria, and ophthalmoplegia, and they were attributed to cranial nerve deficits. Meanwhile, the ocular symptoms correlated with increased venous pressure caused by eyeball draining included decreased vision, increased intraocular pressure, glaucoma, and retinal hemorrhage. The cerebral symptoms were correlated with reflux from the arteriovenous shunt into the superficial middle cerebral vein or the petrosal vein into the perimesencephalic and cerebellar veins. This then leads to infarction or venous congestion in the basal ganglia, brain stem, or cerebellum, which causes seizure or hemorrhage [36]. According to symptom classification, 10, five, seven, and two patients presented with orbital, cavernous, ocular, and cerebral symptoms, respectively. Meanwhile, two patients experienced life-threatening epistaxis and three had intracranial hemorrhage.

In our trauma center, the indications of covered stent insertion are as follows : 1) large size CCF (high flow shunting), 2) life-threatening epistaxis, 3) life-threatening intracranial hemorrhage, and 4) severe cortical venous reflux. Chi et al. [4] described size of CCF according to opacification of anterior cerebral artery (ACA) and middle cerebral artery (MCA) on angiography. Angiograms with opacification of both MCA and MCA were categorized as small size fistula. Angiograms with opacification of either ACA or MCA were categorized as medium size fistula and those without opacification of neither ACA nor MCA were classified as large size fistula. The outcomes immediately after the procedure were classified as total occlusion (no residual shunt), near-total occlusion (minimal residual shunt), and subtotal occlusion (high flow residual shunt). In total, 13 patients underwent follow-up clinical examination and imaging (angiography, computed tomography angiography, or magnetic resonance angiography; Table 1).

Table 1.

Summary of the patients' data

No.	Age	Sex	Trauma mechanism	Initial GCS	Presentation	Basal skull fracture	Fistula point	Size of fistula	Cortical venous reflux
1	36	M	FD	15	1*, 2†, 3‡	-	Lt ICA PG	Large	+
2	63	M	FD	3	Life threatening epistaxis	+	Lt ICA PG	Small	-
3	52	M	FD	15	1*, 2†, 3‡	-	Lt ICA PG	Large	-
4	12	M	FD	15	1*, 2†, 3‡	+	Lt ICA PG	Large	+
5	17	M	MCC	3	Life threatening ICH	-	Lt ICA PG	Small	-
6	31	M	MCC	8	Life threatening ICH, 1*, 3‡	+	Rt ICA PG	Small	-
7	52	M	MCC	13	1*, 2†	+	Lt ICA PG	Small	+
8	23	M	MCC	4	1*, 3‡	+	Rt ICA PG	Large	-
9	62	F	MVC	7	1*, 3‡, 4§	+	Lt ICA PG	Large	-
10	22	M	MCC	7	1*, 2†	+	Lt ICA PG	Medium	+
11	18	M	MCC	3	3‡, 4§	+	Lt ICA PG	Large	+
12	54	F	Iatrogenic	12	Life threatening epistaxis	-	Lt ICA horizontal	Small	-
13	58	F	MVC	7	1*	+	Lt ICA PG	Large	-
14	18	F	MCC	5	Life threatening ICH	+	Rt ICA anterior genu	Small	+
15	63	F	MVC	9	Life threatening ICH, 1*	+	Rt ICA PG	Small	-

^*Orbital symptom.

^†Cavernous symptom.

^‡Ocular symptom.

^§Cerebral symptom.

GCS : Glasgo coma scale, M : male, FD : fall down, Lt : left, ICA : internal carotid artery, PG : posterior genu, MCC : motorcycle crash, ICH : intracranial hemorrhage, Rt : right, F : female, MVC : motor vehicle crash

Endovascular procedure

All procedures were performed under local anesthesia with light sedation. Angiographic evaluation included ipsilateral and contralateral carotid and vertebral angiographies with neck (carotid) compression. Vertebral angiography with ipsilateral ICA compression was extremely effective in identifying the exact fistula points (vertical, genu, and horizontal) of the cavernous ICA. The access was made through the right femoral artery. Then, a 6-F 80-cm long sheath (Shuttle Sheath; Cook, Bloomington, IN, USA) was inserted. After sheath insertion, heparin sodium 3000 IU/mL was administered as a bolus for systemic heparinization and heparin sodium 1000 IU/mL as a bolus every hour to maintain an activated clotting time of 250–300 seconds, except for patients with high-risk hemorrhage. The Shuttle Sheath was located in the distal cervical ICA, and a 6-F guide catheter or intermediate catheter was inserted into the sheath and positioned in the cavernous ICA segment. Subsequently, the microwire was navigated into the second or third segment of the middle cerebral artery. The Graftmaster coronary stent graft system sized 4/19 mm (Abbott Vascular, Rangendingen, Germany) was then advanced over the microwire and placed at the fistula point. Then, the stent was deployed with staged ballooning to achieve a suitable apposition between the stent and vessel wall. If endoleak occurred, multiple balloon inflation (3 to 5 times) was performed by applying a higher to bursting pressure or using a larger balloon. Additional endoleak point coil occlusion with or without a bare stent was applied in most cases of subtotal occlusion after multiple balloon angioplasties.

All patients except emergent cases were premedicated with aspirin 100 mg/day and clopidogrel 75 mg/day orally for 7 days before the procedure. After the procedure, patients with low risk of acute bleeding received aspirin 100 mg and clopidogrel 75 mg for 6 months, followed by 75 mg clopidogrel for >1 year.

RESULTS

The procedures were technically successful in all 15 cases. After covered stent deployment with maximum multiple balloon inflation, endoleak still occurred in six patients (40%). Of these patients, five underwent additional endovascular treatment and one who had minimal endoleak underwent follow-up imaging. Additional fistula point occlusion was achieved using detachable coils (n=2), proximal bare stenting (n=1), stent-assisted coiling (n=1), and second covered stenting (n=1). Immediate angiographic outcomes after the procedure were total occlusion (n=12, 80%), near-total occlusion (n=2, 13%), and subtotal occlusion (n=1, 7%). All patients, except two who died due to multiple severe traumas, underwent follow-up imaging (range, 2 days to 4 years; mean, 15 months). Three patients presented with recurrence, which was completely occluded during the initial procedure. All patients with recurrence received additional treatments (transvenous CS occlusion, stent-assisted coiling via a distal endoleak point, and balloon angioplasty) and achieved complete occlusion. The patients underwent clinical follow-up (range, 2–108 months; mean, 32 months). During follow-up, the outcomes were mild, moderate, and severe in five, five, and three patients (modified Rankin Scale scores of 1–2, 3–4, and 5, respectively), respectively (Table 2).

Table 2.

Procedural results, angiographic and clinical follow-up results

No.	Post stenting procedural endoleak	Management for endoleak	Post procedural angiographic result	Complication	Management of Complication	Postprocedural antiplatelet medication	Follow-up angiographic result		Additional treatment	Final follow-up angiographic result		Clinical follow-up
							Interval	Result		Interval	Result	Interval	mRS
1	-	NA	Total	None	NA	ASA 100 mg+CLO 70 mg	2 Y	Total	None	None	NA	2 Y 9 M	1
2	-	NA	Total	None	NA	None	NA	NA	NA	None	NA	NA	6
3	-	NA	Total	None	NA	ASA 100 mg+CLO 70 dmg	4 Y	Total	None	None	NA	8 Y 11 M	2
4	+	Additional bare stent	Total	None	NA	ASA 100 mg+CLO 70 mg	8M	Total	External carotid artery embolization due to de novo CS dAVF	5 Y 10 M	Total	8 Y 10 M	1
5	-	NA	Total	None	NA	None	NA	NA	NA	None	NA	NA	6
6	+	Additional coiling	Sub-total	None	NA	ASA 100 mg+CLO 70mg	7 M	Total	None	None	NA	4 Y 5 M	2
7	+	Additional coiling	Near-total	None	NA	ASA 100 mg+CLO 70 mg	NA	NA	NA	None	NA	1 Y 6 M	3
8	-	NA	Total	None	NA	ASA 100 mg+CLO 70 mg	7D	Total	None	None	NA	1 Y 5 M	5
9	-	NA	Total	Thromboembolism	IA tirofiban+stent	ASA 100 mg+CLO 70 mg	2 M	Aggravation	Transvenous CS occlusion	4 M	Total	1 Y 5 M	4
10	+	Observation	Near-total	None	NA	ASA 100 mg+CLO 70 mg	6 M	Total	None	None	NA	1 Y 3 M	4
11	+	Additional covered stent	Total	None	NA	ASA 100 mg+CLO 70 mg	13 M	ICA occlusion	None (good collateral)	None	NA	1 Y 1 M	0
12	-	NA	Total	In-stent thrombosis	IA tirofiban	ASA 100 mg+CLO 70 mg	2 D	Aggravation	Stent assisted coiling thorough distal endoleak point	1 Y	Total	1 Y	3
13	-	NA	Total	None	NA	ASA 100 mg+CLO 70 mg	3 M	Aggravation	Balloon angioplasty	5 M	Total	9 M	5
14	+	Stent-assisted coiling	Total	None	NA	ASA 100 mg+CLO 70 mg	9 D	Total	None	None	NA	5 M	5
15	-	NA	Total	Distal ICA dissection	Additional bare stent	ASA 100 mg+CLO 70 mg	7 D	Total	None	None	NA	2 M	4

mRS : modified Rankin Scale, NA : not applicable, ASA : aspirin, CLO : clopidogrel, Y : years, M : months, CS : cavernous sinus, dAVF : dural arteriovenous fistula, D : days, IA : intraarterial, ICA : internal carotid artery

Illustrative cases

Patient 11

An 18-year-old male who presented with left-sided exophthalmos and ptosis 48 days after a motorcycle accident was admitted for the treatment of TCCF. The fistula point was at the posterior genu of the cavernous ICA. Then, a covered stent was advanced to the fistula, and repeated balloon dilatation was performed with gradually increasing pressure. After maximum trial of balloon angioplasty, endoleak persisted at the proximal end of the stent, and the wall apposition of the stent was not good. Then, additional overlapping covered stenting (same size) using the telescoping technique was performed. After the second stent deployment, final angiogram showed complete occlusion of CCF. The patient fully recovered (Fig. 1).

Fig. 1.

An 18-year-old man with left-sided exophthalmos and ptosis in 48 days after motor cycle accident. A : Lateral digital subtraction image of left ICA showing the presence of a TCCF draining via the superior ophthalmic vein, pterygoid plexus, and petrosal sinuses. B : Lateral angiography after distal access guiding catheter (white arrow) delivery to anterior genu of cavernous ICA. Black arrow demonstrated rupture site of ICA. C : Lateral radiography demonstrating deployment of covered stent and white arrow indicated proximal end of the stent. D : Immediate post-procedural angiography confirmed endoleak at proximal end of the stent due to size mismatch. Black arrow confirmed endoleak point. E : Lateral radiography showing additional overlapping covered stent (white arrow) using telescoping technique. F : Final angiogram demonstrating complete occlusion of TCCF. ICA : internal carotid artery, TCCF : traumatic carotid cavernous fistula.

Patient 12

A 54-year-old female patient who presented with life-threatening epistaxis after transsphenoidal pituitary adenoma surgery was transferred from another institution in the province to our hospital. The patient had unstable vital signs, and computed tomography angiography revealed iatrogenic TCCF with pseudoaneurysm formation at the horizontal segment of the cavernous ICA. Emergency covered stent deployment was performed at the fistula; then, complete occlusion of CCF was achieved. However, she presented with recurrent epistaxis 2 days after the covered stent procedure, and angiography confirmed endoleak at the distal end of the stent. After repeated balloon angioplasty, imaging revealed decreased fistula flow. However, remnant flow was still observed. Microcatheter insertion via the fistula point at the distal end of the stent and additional stent-assisted coiling (Solitaire AB 6/30 stent; Covidien, Irvine, CA, USA) were performed. After complete occlusion of the fistula point, the patient’s vital signs improved significantly, and she was discharged with mild vision impairment (Fig. 2).

Fig. 2.

A 54-year-old female with life threatening epistaxis after transsphenoidal pituitary adenoma surgery. A : Lateral angiogram of left ICA demonstrating iatrogenic TCCF with pseudoaneurysm formation (black arrow) at horizontal segment of cavernous ICA. B and C : After the covered stent was deployed (white arrow), complete occlusion of CCF was confirmed. D : Oblique delayed angiography after covered stent deployment showed ICA stenosis distal to the stent, which confirmed vasospasm (black arrow). E : Recurrent epistaxis developed 2 days after covered stent treatment and angiography confirmed endoleak at distal end of the stent (black arrow). F : After repeated balloon angioplasty (black arrowhead), angiography showed a decrease of fistula flow but still persisted. G and H : Microcatheter (white arrow) selection through fistula point at distal end of the stent and additional stent assisted coiling was done (black arrow). I and J : Follow-up anterior and lateral angiography showed stable occlusion of fistula. ICA : internal carotid artery, TCCF : traumatic carotid cavernous fistula.

DISCUSSION

The actual incidence of TCCF is not fully elucidated. Several studies have reported that the incidence ranges from 0.17% to 1.01% in patients with traumatic head and facial trauma [37,44] and is up to 4% in those with basal skull fractures [27]. TCCF could result in permanent neurologic impairment or even death if untreated. Thus, treatment is required to relieve symptoms and control massive bleeding. Nevertheless, the symptoms of TCCF may be masked in patients with head and facial trauma. Hence, its diagnosis could be delayed. TCCF should be considered, and patients with severe head and facial trauma must undergo imaging during the initial evaluation. In our trauma center, computed tomography angiography is performed based on the Denver criteria [11,17].

Although parent artery occlusion was performed in the early stages, the outcomes were not satisfactory. In other words, even if patients had good tolerance to balloon test occlusion, the ischemic complication rates ranged from 5% to 22% [3,21]. Then, a detachable balloon was introduced to prevent fistula formation without parental artery occlusion, and the success rate was 88–98% [7,10,15,20,23,24,29,31,35]. Hence, this method was considered the primary treatment. With the advent of endovascular techniques, the use of detachable coils combined with bare stents has been proven to be an excellent therapeutic strategy for the treatment of DCCF [1,4,19,28,29,33,39]. Although they are excellent therapeutic devices, they cannot be used in some cases, which include an extremely large orifice to cover with detachable balloons or coils and sharp osseous fragments within the sinus that cause premature balloon deflation. Moreover, these devices have disadvantages. That is, there is a risk of cranial nerve palsy caused by mass effect. Furthermore, parental artery occlusion or ischemic events caused by coil migration could occur [8,13,18,20,23,39]. Currently, the use of detachable balloons may also be limited by their availability [12].

A recent study used a covered stent in DCCF and reported the outcomes [2,5,12,16,25,26,38,40,41]. Covered stents can be used in some conditions in which detachable balloons and coils cannot be utilized. The reported success rate to date of detachable balloon, flow diverter and covered stent for occlusion of TCCF as primary treatment modality was 55–98% [8,14,20], 71% [42], and 75–100% [12,26,41], respectively and our results were similar with previous reports. Moreover, it has advantages in the concept of one-step and time-saving treatment in emergency situations. The Graftmaster coronary stent graft system described in this study was originally designed for the management of coronary perforations in relatively straight coronary vessels [2,34,41]. Therefore, there is a limit in the application of covered stents with a stiff delivery system to the tortuous cavernous ICA system, which causes endoleak. This condition was correlated with poor stent vessel apposition or size mismatch. Previously, endoleak was expected to disappear and was not actively treated. If endoleak persisted in follow-up imaging, additional second bare stent placement or CS occlusion was performed [2,5,12,16,25,26,38,40,41]. We completed the first procedure with total occlusion in all patients, except in three with tolerable remnant endoleak. On follow-up imaging, three patients who had complete occlusion during the initial procedures presented with CCF recurrence. According to a root cause analysis, one patient who had low volume status was admitted due to severe epistaxis after surgery for pituitary adenoma. Due to excessive blood loss, the ICA collapsed and the covered stent was positioned in the temporarily constricted vessel. After volume resuscitation, vasospasm was treated and size mismatch between the covered stent and the dilated vessel caused endoleak. In another case, endoleak was believed to be attributed to incomplete apposition between the covered stent and the vessel wall at the proximal end. According to a previous study, the incidence of endoleak varies from 9% to 83% [16,25,26,34,40].

To reduce the incidence rate of endoleak without destructive procedure such as CS occlusion, some techniques including balloon angioplasty and use of longer and oversized covered stents were applied [16,25,26,40]. If the endoleak persisted in such attempts, we sealed the endoleak with a microcatheter via the leakage point and occluded it with detachable coils. Herein, we reported four cases of fistula point microselection and coil occlusion for endoleak, three of which were performed at the time of primary covered stent placement and one during the subsequent angiography after the placement of a covered stent. There might be limitations in vessel wall apposition due to shape and size mismatch, particularly at the proximal and distal ends, which usually cause type 1 endoleak [16,43].

Endovascular aortic aneurysm repair for anatomically suitable abdominal aortic aneurysms has gained wide acceptance in the past decade [9], and some studies have performed prophylactic proximal bare stent placement in hostile necks because patients with such anatomy are at an increased risk of proximal endoleak (type 1a) and migration, resulting in adverse events in up to 70% of cases [6,22,32]. We believe that prophylactic bare stent placement might also be applied to an intracranial covered stent. One patient with recurrent symptoms experienced complete occlusion during the initial procedure. However, the final angiographic imaging showed proximal end mismatch. Thus, endoleak was likely to occur, which could have been prevented with a prophylactic bare stent (patient number 13). The placement of prophylactic bare stent could maximize apposition of the covered stent to the vessel wall, and the use of a prophylactic bare stent with or without endoleak during the initial procedure is believed to reduce the rate of postprocedural endoleak. The limitations of present study include its retrospective nature, the recruitment of a limited number of patients, and relatively short follow-up duration. However, we presented indications of covered stent as a first-line treatment for TCCF and stent-based intracranial artery reconstruction could become the first-line treatment modality for TCCF.

CONCLUSION

TCCF is fatal and life-threatening; therefore, it must be considered and diagnosed in patients with severe head and facial trauma. Covered stent is the most reconstructive method, with a high total occlusion rate. Although endoleak has been the primary concern in the use of a covered stent, it could be managed with detachable coils at the leakage point or prophylactic bare stent in specific cases. Covered stents could be considered as the first-line treatment for TCCF. However, long-term follow-up and larger-scale studies are still warranted to further develop the specifications and indications of such device.